Logo
x

Search

Subscribe Now

Combination

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

  • October 13, 2021
Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

  • March 4, 2021
BMS Report Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III CheckMate -9ER Trial for 1L Treatment of Advanced Renal Cell Carcinoma

BMS Report Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III CheckMate -9ER Trial for 1L Treatment of Advanced Ren...

  • February 9, 2021
Innovent's Tyvyt (sintilimab) + Pemetrexed and Platinum CT Receives NMPA's Approval as 1L Therapy with Non-squamous Non-Small Cell Lung Cancer

Innovent's Tyvyt (sintilimab) + Pemetrexed and Platinum CT Receives NMPA's Approval as 1L Therapy with Non-squamous Non-Small Cell...

  • February 3, 2021
Merck's Report Results of Keytruda (pembrolizumab) in Combination With Ipilimumab vs Keytruda Monotherapy in P-III KEYNOTE-598 for Metastatic Non-Small Cell Lung Cancer Patients

Merck's Report Results of Keytruda (pembrolizumab) in Combination With Ipilimumab vs Keytruda Monotherapy in P-III KEYNOTE-598 for...

  • February 1, 2021
Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) as 1L Therapy for Hepatocellular Carcinoma

Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) as 1L Therapy for Hepatocellular Carcin...

  • January 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.